South Korea’s cell and gene therapy surge

South Korea’s cell and gene therapy (CGT) landscape is highly dynamic, as observed from regulatory approvals, clinical development, and manufacturing activity.

The Ministry of Food and Drug Safety (MFDS) has approved 15 CGT products to date, including 12 cell therapies and three gene therapies, indicating a conducive environment for CGT development. However, it is important to note that most developments and approvals have been concentrated in regenerative stem cell therapies, with comparatively fewer developments in more complex ones, such as in vivo gene editing and in vivo engineered cell therapies.

Research Manager, Ruplekha Choudhurie spoke to BioSpectrum Asia regarding the above.

To read the full article, visit BioSpectrum Asia